| Date | Title | Description |
| 30.08.2024 | Nifty logs gains for record 12th straight session, Sensex up 230 pts as pharma, realty stocks rally | Cipla, Bajaj Finance, Divis Labs, M&M, and Bajaj Finserv were the top gainers on the Nifty.
Benchmark indices Nifty and Sensex held steady in positive territory to end the day at record closing on August 30, driven by a sharp rally in r... |
| 22.08.2024 | Mid-day Mood | Nifty, Sensex hold firm as PSU Banks, FMCG stocks shine; VIX eases 2% | The India VIX, a measure of market anxiety, declined slightly by over 2 percent, settling at 13.
Benchmark indices NSE Nifty 50 and Sensex managed to hold on to gains following a strong start to trading on August 22 as positive global cues ... |
| 28.07.2024 | Cipla expects to commence supplies to US from China plant later this year | Drug major Cipla expects to commence supplies to the US market from its China facility in the second half of the current fiscal after getting approval from the American health regulator, according to its MD and global CEO Umang Vohra.
Addre... |
| 25.07.2024 | The Intersection of Employment History and Financial Opportunities**
** | ** In the world of finance, your employment history is more than just a line on your resume. It’s a key that unlocks doors to credit cards, loans, and financial stability. Think of it as a bridge connecting your past work experience to your... |
| 25.07.2024 | Market Pulse: A Cautious Dance on Dalal Street Amid Earnings and Economic Signals**
** | ** The Indian stock market is a living organism, pulsating with energy and uncertainty. As we approach a critical juncture—the Union Budget 2024—investors are treading carefully. The recent sell-off has left the benchmark indices gasping fo... |
| 25.07.2024 | Large cap funds: A suitable investment option in a growing India | Pune, Maharashtra, India
Equity investments offer significant growth potential in the long-term, but the associated risks can make investors apprehensive. Large cap mutual funds present a unique opportunity to investors to access the wealth... |
| 21.07.2024 | Dalal Street Week Ahead: Union Budget, Q1 Earnings, US GDP among 10 key factors to watch | Dalal Street Week Ahead
Market participants remain cautious ahead of the key event, the Union Budget 2024, scheduled for next week. The benchmark indices lost about a percent due to Friday's sell-off, ending the week flat with a positive bi... |
| 11.07.2024 | Five Industries Set to Revolutionize in India Utilizing AI and Deep Tech AI and Deep Tech are experiencing a huge surge in the Indian market, surpassing the e-commerce boom of the mid-2010s | Some years ago, Artificial Intelligence (AI) and Deep Tech were part of fantasy movies and we never imagined using them in our daily lives. But if you look at the recent data from Indian industries, you will be surprised to see that several... |
| 05.07.2024 | Cipla is now completely professionalised, says MD and Global CEO Umang Vohra | Cipla has “completely professionalised” over the last 10 years, said Cipla Managing Director and Global Chief Executive Umang Vohra, of a transformative journey undertaken even as two of its key promoters who built the business do not inten... |
| 24.06.2024 | Sun Pharma completes merger of Taro | Drugmaker Sun Pharmaceutical Industries has completed the merger of Israel’s Taro Pharmaceutical Industries, ending a long drawn-out feud between the two companies, that played out across multiple geographies.
Also read:Cipla, Sun Pharma in... |
| 21.06.2024 | Cipla, Sun Pharma ink non-exclusive agreement with Takeda on acid-reflux drug | Drugmakers Cipla and Sun Pharma have signed non-exclusive patent license agreements with Takeda Pharmaceutical Company Limited, respectively, for ‘Vonoprazan’ for India. The drug is used to treat acid-related illnesses among patients.
Cipla... |
| 21.06.2024 | Weight-loss-drug frenzy lures rich Indians to brave the gray market | - |
| 30.05.2024 | Why did investors dump Marksans Pharma shares post Q4 results? Know here | - |
| 29.05.2024 | Health secy highlights India's achievements, future goals at WHO assembly | - |
| 27.05.2024 | Indian pharmaceutical companies likely to cash in on US drug shortages | - |
| 24.05.2024 | Weak Q4 due to lower growth may be rare bitter pill for Sun Pharma | - |
| 22.05.2024 | Buy ideas for May 22: Britannia, Cipla; check target prices | - |
| 22.05.2024 | Cipla receives USFDA approval to market Lanreotide injection in US | - |
| 22.05.2024 | Cipla receives final approval for the generic version of Somatuline® Depot (Lanreotide) Injection 120 mg/ 0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL | MUMBAI, India and WARREN, N.J., May 22, 2024 /PRNewswire/ -- Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") and its wholly owned subsidiary Cipla USA Inc., (hereafter referred to as "Cipla&qu... |
| 22.05.2024 | Cipla rallies 4% on US FDA approval to market Lanreotide injection | - |
| 21.05.2024 | India on cusp of long-awaited economic take-off: RBI monthly bulletin | - |
| 21.05.2024 | Expect formulations biz to outpace API biz: Biocon Group CEO Peter Bains | - |
| 17.05.2024 | Indian pharma firms supplied 47% of all generic prescriptions in US in 2022 | - |
| 16.05.2024 | Cipla promoters sell 2.53% stake worth Rs 2,637 cr to fund philanthropy | - |
| 15.05.2024 | Bharti Airtel, Cipla, Paytm, Colgate among seven stocks to track on May 15 | - |
| 15.05.2024 | Promoter group to sell 2.53% stake worth $316 million in Cipla: Report | - |
| 15.05.2024 | Cipla promoters sell 2.5% stake; Picked up by global, domestic funds | Drugmaker Cipla promoters sold over 2 crore shares in the company or 2.53 per cent of its equity in a block deal at a price of ₹1,345 for a total aggregate of ₹2,690 crore. The shares were picked up by a host of global and domestic funds, e... |
| 15.05.2024 | Cipla zooms 5% on 2.53% stake sale by Hamied family, Okasa Pharma | - |
| 14.05.2024 | Cipla: Timely new launches, India outperformance key for margin gains | - |
| 14.05.2024 | Cipla promoters to sell up to 2.5% stake for ₹2637 crore | Pharma major Cipla’s promoters and promoter group entities are looking to sell up to 2.53 per cent stake in the company through a block deal for a total value of ₹2,637 crore, sources said.
The deal value is calculated at the floor price wi... |
| 13.05.2024 | Sensex, Nifty close higher after falling 1% intraday; analysts say 'exercise caution' | Broader markets mixed
Trade Watchlist Portfolio
Message
Set Alert
livebselivenselive
Volume
Todays L/H
More
×
The Sensex and Nifty 50 fully recovered from the day's lows on May 13 and closed in green after falling almost 1 percent each in t... |
| 10.05.2024 | Cipla Q4 results: Profit rises 78.5% to Rs 939 crore, revenue up 7% | - |
| 10.05.2024 | Cipla keen on obesity segment, to bring out products on its own or though partnership | Cipla is looking at the obesity and weight-loss drugs category, either on its own or in partnership, its top management said.
The company has an existing partnership with American company Eli Lilly, with whom it is culturally aligned, said ... |
| 08.05.2024 | Dr Reddy's Labs slumps 5% as brokerages give 'Reduce' call post Q4 earnings | - |
| 08.05.2024 | USFDA issues Form 483 with 1 inspectional observation to Cipla's Maha unit | - |
| 06.05.2024 | Dr Reddy's Q4 Preview: Here's what key brokerages expect from its results | - |
| 06.05.2024 | Anand Rathi recommends buy on Dr.Reddys, Cipla and Piramal Enterprises | - |
| 05.05.2024 | Cipla, Glenmark recall drugs from US over manufacturing issues: USFDA | - |
| 04.05.2024 | Productivity loss due to oral cancer in India in 2022 at $5.6 bn: Study | - |
| 04.05.2024 | India raises issue of pharma pricing control in Australia on generic drugs | - |
| 03.05.2024 | Delhi HC directs action against use of oxytocin in dairy colonies | - |
| 02.05.2024 | India, New Zealand look to boost collaboration in pharma, digital trade | - |
| 01.05.2024 | Mizoram sees alarming surge in TB deaths, 108 succumb to disease in 2023 | - |
| 29.04.2024 | India's Strategic Moves in West Asia and Beyond | India is making strategic moves in West Asia and beyond to expand its ties and reduce its reliance on China.
India is set to sign a trade deal with Oman, strengthening its ties in West Asia. This move is aimed at boosting India's presence i... |
| 29.04.2024 | Stock to Watch, April 29: ICICI Bk, HCL Tech, YES Bk, Ircon, Maruti, Cipla | - |
| 27.04.2024 | India set to sign trade deal with Oman to expand its West Asia ties | - |
| 24.04.2024 | Pharma exports rise around 10% to $27.9 billion, US biggest importer | - |
| 19.04.2024 | Cipla gets Rs 1.83 cr penalty for claiming inadmissible transitional credit | - |
| 17.04.2024 | India not reaping benefits of its demographic dividend: Raghuram Rajan | - |
| 16.04.2024 | Cipla Health signs agreement, strengthens beauty play with Ivia's brands | - |
| 12.04.2024 | Some parties seek LGBT vote as most Indians disapprove of homosexuality | - |
| 09.04.2024 | NSE Unveils 4 New Indices in Capital Market and F&O Segment | The National Stock Exchange (NSE) has rolled out four new indices today, spanning both the capital markets and Futures and Options (F&O) segments. These indices aim to diversify investment opportunities and track specific sectors with p... |
| 08.04.2024 | Biocon leads India's push into anti-obesity drugs as patents lapse | Biocon Ltd. is pivoting to anti-obesity therapies as patents for the blockbuster medications start to expire, unleashing a wave of generic supply for the market that’s expected to touch $100 billion by 2030.
The Bengaluru-based firm has sco... |
| 08.04.2024 | NSE to introduce 4 new indices in capital market and F&O segment from today | The National Stock Exchange (NSE) is launching four new indices on Monday, in both the capital markets and Futures and Options (F&O) segments. It had made the announcement on April 3.
These four new indices are Nifty Tata Group 25 per c... |
| 07.04.2024 | Sanofi eyes speedy growth in India, plans fast-tracking of product pipeline | Aiming for a "fair share" in the Indian pharmaceutical market, French drug major Sanofi plans to introduce new drugs and enhance localisation while expanding the reach of its existing brands through collaboration with domestic dru... |
| 05.04.2024 | Zomato hits new high in subdued market; stock zooms 55% thus far in CY24 | Shares of Zomato hit a new high of Rs 191.25, gaining 2 per cent on the BSE in Friday's intra-day trade in an otherwise subdued market on expectations of healthy earnings. In comparison, the S&P BSE Sensex was down 0.2 per cent at 74,07... |
| 04.04.2024 | Lupin appoints Dr Ranjana Pathak as Chief Quality Officer | Drugmaker Lupin Limited has appointed Dr Ranjana Pathak as Chief Quality Officer, succeeding Johnny Mikell who will be retiring, the company said.
With over three decades of industry experience, Pathak will oversee all aspects of quality an... |
| 27.03.2024 | Closing Bell: Nifty above 22,100, Sensex up 526 pts; capital goods, realty, auto shine | - |
| 26.03.2024 | Sanofi, Cipla join hands to expand reach of CNS portfolio in India | Sanofi India and Cipla announced on Tuesday an exclusive partnership to boost access to Sanofi's Central Nervous System (CNS) medications across India.
Cipla will leverage its extensive network to distribute Sanofi's CNS portfolio, includin... |
| 06.03.2024 | Global Bevacizumab Biosimilars Market Outlook 2024-2028 & 2033 Featuring Cipla, Reliance Lifesciences, Genentech, Fujifilm Kyowa Kirin Biologics, and Pfizer | - |
| 07.07.2023 | Cipla Issues Voluntary Nationwide Recall of Six Batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) Due to Container Defect | COMPANY ANNOUNCEMENT
When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company. Read Announcement
Summary
Comp... |
| 02.01.2023 | German biotech startup Ethris to raise €15M from Cipla EU to develop mRNA-based therapies | Bayern-based Ethris, a company that claims to be paving a new path from genes to therapeutic proteins using its messenger RNA technology platform, announced on Thursday, December 29, that it will raise €15M from Cipla EU — the wholly-owned ... |
| 18.08.2022 | Drug Delivery Devices Market Estimates by Production 2022: Cipla, Baxter International, Nipro Corporation, and Roche | Drug Delivery Devices
Drug Delivery Devices market size is estimated to be USD 100.1 billion in 2029 from USD 85.1 billion in 2022, with a CAGR change of 4.50% between 2022 to 2029. NEW YORK, NY, UNITED STATES, August 18, 2022 /EINPresswire... |
| 18.07.2022 | Digital health news, funding roundup in the prior week; July 18, 2022 | Biden issues abortion guidelines; UnitedHealth and Optum combine assets; Redi partners with Labcorp
Top Health News
Infermedica launched its Medical Guidance Platform to automate the entire primary care journey. The platform now includes th... |
| 08.02.2022 | Cipla to Procure Power from AMP Energy’s 16 MW Open Access Solar Project | Arjun Joshi
Arjun Joshi is a staff reporter at Mercom India. Before joining Mercom, he worked as a technical writer for enterprise resource software companies based in India and abroad. He holds a bachelor’s degree in Journalism, Psychology... |
| 04.02.2022 | Cipla : Acquisition | 4th February, 2022 (1) BSE Limited (2) National Stock Exchange of India Limited
Listing Department, Listing Department
Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor,
Dalal Street, Plot no. C/1, G Block,
Mumbai 400 001 Bandra Kurla Co... |
| 29.01.2022 | Cipla : Earnings Call Transcript Q3FY22 | 29th January, 2022 (1) BSE Limited (2) National Stock Exchange of India Limited
Listing Department, Listing Department
Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor,
Dalal Street, Plot no. C/1, G Block,
Mumbai 400 001 Bandra Kurla Co... |
| 25.01.2022 | Cipla : Extract of Unaudited Consolidated Financial Results – 31st December 2021 | 25th January, 2022 (1) BSE Limited (2) National Stock Exchange of India Limited
Listing Department, Listing Department
Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor,
Dalal Street, Plot no. C/1, G Block,
Mumbai 400 001 Bandra Kurla Co... |
| 25.01.2022 | Cipla : Q3 FY22 Investor presentation | Investor Presentation
Q3FY22
January 25, 2022
DISCLAIMER
Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These for... |
| 25.01.2022 | Cipla : Unaudited financial results (standalone and consolidated) for the quarter and nine months ended 31st December 2021 | 25th January, 2022 (1) BSE Limited (2) National Stock Exchange of India Limited
Listing Department, Listing Department
Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor,
Dalal Street, Plot no. C/1, G Block,
Mumbai 400 001 Bandra Kurla Co... |
| 25.01.2022 | Cipla : Q3 FY22 Press release | Cipla announces Q3 FY22 results
Robust momentum across key markets. Strong traction in One-India and
US business. Delivery continues to be ahead of internal targets.
Sequentially higher EBITDA margin
Income from Operations EBITDA PAT
INR 5,... |
| 13.01.2022 | Cipla : wins the prestigious Frost & Sullivan and TERI's Sustainability 4.0 Award 2021 as “Challenger in Mega Large Business Pharma Sector” | Mumbai, India; 13 January 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") announced today that it has been awarded winner as a "Challenger in Mega Large Business Pharma Sector" by F... |
| 12.01.2022 | Cipla : JP Morgan Healthcare Conference | JP Morgan Healthcare Conference
Umang Vohra, MD & Global CEO
January 2022
Disclaimer
Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward- lo... |
| 28.12.2021 | Cipla : receives Emergency Use Authorisation(EUA) to launch oral anti-viral drug Cipmolnu®(Molnupiravir 200mg) in India for treatment of adult patients with COVID-19, with SpO2>93% and with high ri... | Mumbai, India; December 28, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") announced today that it has been granted Emergency Use Authorisation(EUA) permission by the Drug Controller General... |
| 17.11.2021 | Cipla launches Spirofy®: Strengthens its lung leadership position by facilitating early diagnosis for COPD | Spirofy®: India's first pneumotach based portable wireless Spirometer for diagnosis of Chronic Obstructive Pulmonary Disorder (COPD) and asthma
COPD1 is the 2nd most common cause of deaths in India2
Mumbai, India; November 17, 2021: Cipla L... |
| 29.10.2021 | Earnings Call Transcript Q2FY22 | "Cipla Limited Q2 FY-22 Earnings Conference Call"
October 26, 2021
MANAGEMENT: MR. UMANG VOHRA - MANAGING DIRECTOR &
GLOBAL CHIEF EXECUTIVE OFFICER, CIPLA LIMITED
MR. KEDAR UPADHYE - GLOBAL CHIEF FINANCIAL
OFFICER, CIPLA LIMIT... |
| 26.10.2021 | Q2 FY22 Investor presentation | Investor Presentation
Q2FY22
October 26, 2021
DISCLAIMER
Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These for... |
| 26.10.2021 | Q2 FY22 Press release | Cipla announces Q2 FY22 results
Growth momentum across core therapies and markets continue
and sustained cost control drives EBITDA margin of 22.2%
Income from Operations EBITDA PAT
INR 5,520 Cr INR 1,226 Cr │22.2%1 INR 711 Cr │12.9%1
10% Y... |
| 26.10.2021 | Extract of Unaudited Consolidated Financial Results – 30th September 2021 | 26th October, 2021 (1) BSE Limited (2) National Stock Exchange of India Limited
Listing Department, Listing Department
Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor,
Dalal Street, Plot no. C/1, G Block,
Mumbai 400 001 Bandra Kurla Co... |
| 12.08.2021 | Cipla receives final approval for generic version of Novartis Pharmaceuticals Corporation Durezol® (Difluprednate Ophthalmic Emulsion 0.05%) | |
| 27.06.2021 | ExplainSpeaking: Alternatives to the RBI printing money for a fresh Covid relief package | Dear Readers,
Last week, T V Narendran, the CEO and Managing Director of Tata Steel Limited as well as the new president of the Confederation of Indian Industry (CII), urged the government to provide a fresh fiscal stimulus to boost demand ... |
| 23.06.2021 | Cipla receives final approval for generic version of Sunovion Pharmaceuticals, Inc.'s Brovana® (Arformoterol Tartrate Inhalation Solution 15 mcg/ 2mL) | |
| 02.03.2021 | Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX® (Sumatriptan Nasal Spray, 20 mg)
USA - English
España - español
USA - English | |
| 11.12.2020 | Cipla Announces Settlement of REVLIMID® (lenalidomide) Capsules Patent Litigation | |
| 18.11.2020 | Cipla launches 'Covi-G' for COVID-19 rapid antibody detection
USA - English
USA - English
USA - English
USA - English
USA - English
USA - English
USA - English
España - español
Россия - Pусск... | |
| 28.09.2020 | Cipla receives final approval for generic version of Biogen IDEC Inc.'s Tecfidera® (Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pack) | |
| 20.11.2014 | Cipla Announces a Distribution Agreement with Serum Institute of India for Affordable Paediatric Vaccines in Europe | Mumbai, Maharashtra, India
Cipla Europe NV (“Cipla”), a global pharmaceutical company is delighted to announce that it has signed a distribution agreement with Serum Institute of India Ltd. (SII) – a global leader in the production of vacci... |
| 15.09.2014 | Cipla Enters Into a Licensing Agreement with Gilead to Increase Access to Hepatitis C Treatment | Mumbai, Maharashtra, India
Cipla Limited, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients today announced that it has signed a non-exclusive licensing agreement wi... |
